

03C0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Michael Z. Gilman

Serial No.: 09/676,834 ✓

Filed: September 29, 2000

For: NEW APPLICATIONS OF GENE THERAPY TECHNOLOGY

Attorney Dkt: APBI-P04-340 (formerly APV-340.04)

Commissioner for Patents

Washington, D.C. 20231

Attn: Customer Service Center  
Initial Patent Examination Division

**TRANSMITTAL LETTER**

Dear Sir:

Responsive to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed August 2, 2001, the following is enclosed:

1. Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pp.);
2. Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 p.);
3. Postpaid Return Postcard.

The undersigned authorizes the charging of any additional fees and crediting of any overpayment associated with this communication to our Deposit Account No. 18-1945. The undersigned requests any extensions of time necessary to respond. .

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:

August 15, 2001

Date

*Joan Glassman*  
JOAN GLASSMAN

Respectfully submitted,

ROPHES & GRAY, LLP

Matthew P. Vincent, Reg. No. 36,709  
One International Place  
Boston, MA 02110  
Tel. (617) 951-7000

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/676,834	09/29/2000	Michael Z. Gilman	APBI-P04-340

28120  
ROPES & GRAY  
ONE INTERNATIONAL PLACE  
BOSTON, MA 02110-2624

CONFIRMATION NO. 4232  
CORRECTION COVER LETTER



\*OC000000006302663\*


Date Mailed: 08/02/2001

**COVER LETTER FOR CORRECTION OF PREVIOUS NOTICE**

The Notice mailed on 11/20/2000 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202  
PART 2 - COPY TO BE RETURNED WITH RESPONSE



**UNITED STATES PATENT AND TRADEMARK OFFICE**

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/676,834	09/29/2000	Michael Z. Gilman	APBI-P04-340

28120  
ROPES & GRAY  
ONE INTERNATIONAL PLACE  
BOSTON, MA 02110-2624

**CONFIRMATION NO. 4232**

**FORMALITIES LETTER**



\*OC00000006373267\*

Date Mailed: 08/02/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*Ngm*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE